ZHAOKE OPHTH-B(06622): The National Medical Products Administration has accepted the new drug application for NVK002 (0.02% atropine sulfate eye drops) for the treatment of progressive myopia in children.
Zhaoke Ophthalmology-B (06622) announced that the China National Medical Products Administration recently accepted one of the company's core products...
ZHAOKE OPHTH-B (06622) announced that the China National Medical Products Administration recently accepted the new drug application for NVK002 (0.02% atropine sulfate eye drops), one of the company's core products used to treat progressive myopia in children. The new drug application is classified as a Class II innovative drug.
Earlier on January 2, 2025, the company announced that the Chinese National Medical Products Administration had accepted a simplified new drug application for NVK002 (0.01% atropine sulfate eye drops) for the treatment of progressive myopia in children. The drug is currently undergoing the review process.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
